Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. (SUPN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
supn · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Supernus Pharmaceuticals, Inc. (SUPN) measures how much investors pay for each dollar of the company's trailing earnings. SUPN's current PE ratio of N/A is calculated by dividing its stock price of $44.48 by its TTM earnings per share of -$0.50.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 13 fiscal years · Front-end computedMinQ1 · 25%27.0x
MedianQ3 · 75%1199.3x
Max
At N/A, SUPN's current P/E is lower than in 0% of its annual fiscal year readings over the past 13 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Supernus Pharmaceuticals, Inc.You SUPN | $2.6B | N/A | — | -$0.50 |
 Amneal Pharmaceuticals, Inc. AMRX | $4.4B | 54.80x | +116.5% | $0.23 |
 Bausch Health Companies Inc. BHC | $1.9B | 16.14x | -36.2% | $0.43 |
 CG Oncology, Inc. Common stock CGON | $4.8B | N/A | — | -$2.08 |
 Centessa Pharmaceuticals plc CNTA | $6.1B | N/A | — | -$1.46 |
 GRAIL, Inc. GRAL | $2.6B | N/A | — | -$11.11 |
 HUTCHMED (China) Limited HCM | $1.9B | 4.99x | -80.3% | $2.67 |
Industry Average 3 peers with valid PE | — | 25.31x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.68 | — | |
2024-12-31 FY2024 | 26.97x | $1.34 | -97.8% | |
2023-12-31 FY2023 | 1199.30x | $0.02 | +3703.6% | |
2022-12-31 FY2022 | 31.53x | $1.13 | +8.8% | |
2021-12-31 FY2021 | 28.98x | $1.01 | +177.9% | |
2020-12-31 FY2020 | 10.43x | $2.41 | -5.2% | |
2019-12-31 FY2019 | 11.00x | $2.16 | -29.3% | |
2018-12-31 FY2018 | 15.56x | $2.13 | -55.9% | |
2017-12-31 FY2017 | 35.31x | $1.13 | +157.8% | |
2016-12-31 FY2016 | 13.69x | $1.84 | -69.9% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Supernus Pharmaceuticals, Inc. (SUPN) measures how much investors pay for each dollar of the company's trailing earnings. SUPN's current PE ratio of N/A is calculated by dividing its stock price of $44.48 by its TTM earnings per share of -$0.50.
Frequently asked questions
SUPN pe ratio · 6 questionsSUPN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $44.48 and TTM EPS of -$0.50. Data sourced from Financial Modeling Prep via SUPN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Supernus Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09